

HERAMED ANNOUNCES NEW COMMERCIAL AGREEMENT WITH GLOBAL TECHNOLOGY LEADER PHILIPS TO OFFER NEXT-GENERATION DIGITAL MATERNITY CARE IN THE U.S.

HeraMED Limited (ASX: HMD) ('HeraMED' or the 'Company'), a medical data and technology company pioneering digital maternity care, is pleased to announce that it has entered into a commercial agreement with Telcare Medical Supply LLC, a U.S. based subsidiary of global health technology leader Royal Philips ("Philips") (NYSE:PHG) to offer a complete and integrated digital maternity care solution for U.S. hospitals and health systems.

Philips will provide its market-leading monitoring devices, logistics, and technical support. The combination of Philips device portfolio and infrastructure with HeraMED's HeraCARE digital platform, which enables remote patient monitoring, personalised care plans, and patient engagement tailored specifically to the maternity and postpartum journey, will create a digital solution for maternity care at scale for U.S. hospitals and health systems.

Anoushka Gungadin, Managing Director and Chief Executive Officer of HeraMED, said:

"We are thrilled to be working with Philips, a global leader in connected health, to transform how maternity care is delivered across the United States. This is the first step in what we hope is a broader and deeper relationship. By combining Philips' trusted monitoring technology and healthcare infrastructure with HeraCARE's intelligent digital engagement and care management platform, we're creating an integrated solution that supports mothers and clinicians through the entire maternity journey – from prenatal to postpartum care."

The solution offers hospitals and health systems a ready-to-use, configurable remote patient monitoring (RPM) ecosystem that empowers care teams to monitor, engage, and educate women through pregnancy and postpartum. The platform integrates device data, clinical dashboards, secure communication, and educational content to deliver a connected and patient-centred model of maternity care.

HeraMED will now begin presenting this new digital solution to identified U.S. health systems seeking scalable digital solutions for pregnancy and postpartum care.

Additional details on Commercial Agreement

- The Company will update the market when hospitals and health systems are formally engaged under the commercial agreement.
- No revenue will be generated until such engagements occur.
- The initial term of the commercial agreement is 12 months with an option to renew and either party can terminate the agreement by providing 30 business days' notice.

ENDS

This announcement has been authorised by the Board of HeraMED Limited.

HeraMED Limited**Managing Director & CEO**

Anoushka Gungadin

M: +61 431 131 649

E: anoushka@hera-med.com**Company Secretary**

Cameron Jones

T: +61 400 086 399

E: cameron.jones@bio101.com**Chairman**

Tim Chapman

T: +61 419 897 062

E: tchapman@claritycap.com.au**About HeraMED Limited (ASX: HMD)**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

About Philips (NYSE:PHG):

<https://www.philips.com/a-w/about>